Objectives. To provide students with an understanding of the principles and applications of human genetics and genomics in drug therapy optimization, patient care, and counseling. Design. A 2-credit hour course entitled Principles of the Human Genome, Pharmacogenomics, and Bioinformatics was offered to third-professional year PharmD students. Written examinations, in-class exercises, and a written paper evaluating the current literature were used to evaluate student learning. Assessment. Student course ratings on the pedagogical format of the course and the relevance of course material to professional practice have improved significantly since first implementation in 2002. Conclusion. This course provided pharmacy students with an understanding of pharmacogenetics ranging from genetic principles and the inheritance of complex traits to specific examples of pharmacogenomics in drug therapy.
INTRODUCTION
The concept that human genetic variation affects how individuals respond to drugs has been recognized for over 45 years. The term pharmacogenetics was first coined by Vogel 1 in 1959 following an earlier summary by Motulsky 2 concerning inter-individual drug response and its relationship to genetics (as understood to be the study of patterns of inheritance). Now, as a result of the genetic information made available through the Human Genome Project, the extent to which this information is accumulating in the biomedical and pharmaceutical literature is staggering. Equally exciting is the promise this information holds in understanding the role that encoded variation in complex biological systems has in human drug response. Such information will ultimately transform the health sciences and require health professionals to be knowledgeable about a vast new area of basic science: genomics. 3 The integration of this knowledge in pharmacy education is particularly important since genomics probably will be felt most immediately in the pharmaceutical sciences since drug efficacy and toxicity are more tractable problems than many more complex, multifaceted health issues (eg, cancer, obesity, cardiovascular disease, mental disorders). Drugs having relatively specific targets, and polymorphisms in one or a few genes (coding for drug transporters or drug metabolizing enzymes) may alter drug disposition.
The need for pharmacogenetics and pharmacogenomics in pharmacy school curricula is immediate and, in fact, has been included in the recent ACPE Standards 2006. 4 In a survey of 377 community pharmacists in the United States, less than 50% were satisfied with their knowledge of the Human Genome Project, genetic testing, and pharmacogenetics. 5 Thus, practicing pharmacists realize the need for a better background in genetics and its application to pharmaceutical principles. This need has also been recognized among pharmacy educators. 6 To date, pharmacogenomics has not been consistently incorporated into the curriculum for the doctor of pharmacy degree. In a 2004 survey of 85 colleges and schools of pharmacy in the United States, of the 41 respondents, only 16 schools provided any content on pharmacogenetics or pharmacogenomics to their professional students. 
DESIGN
A new course titled Principles of the Human Genome, Pharmacogenomics, and Bioinformatics was designed to be offered during the fall semester of the thirdprofessional year. The course was first offered in spring 2002 and then every fall semester beginning in 2002. The course was assigned 2 credit hours and is a part of the required curriculum. The course was administered by 1 faculty member, but 5 faculty members from the Department of Pharmaceutical Sciences and the Department of Pharmacy Practice provided guest lectures in key areas during the final 5 weeks of the course. These guest lectures were intended to provide specific examples of the role of pharmacogenetics and pharmacogenomics technologies in clinical and research settings. The general educational outcomes of the course were based on the American Society of Human Genetics guidelines for a medical school core curriculum in genetics. 8 The The class met once a week for 100 minutes. Lecture topics are shown in Table 1 . Following an introduction to the history of pharmacogenetics and pharmacogenomics in the first class, a basic review of DNA and RNA structure leading on to mechanisms of gene expression and gene regulation was presented in the second week. During the third week of the course, how genetic traits are acquired, maintained, and distributed among populations (traditional population genetics) was discussed. Complex or multifactorial patterns of inheritance were covered in the fourth week, along with issues relating to genetic mapping of complex traits. In the first 4 weeks of the course, each of these basic genetic concepts were presented using examples from the pharmaceutical sciences. For example, population genetics and allelic differences among populations were discussed in the context of the geographic distribution of variants for many drug metabolizing enzymes. 9 In the fifth and sixth weeks, the structure, evolution, and organization of genomes and the sorts of bioinformatic tools available on the Internet were covered. Also covered was a brief discussion of the most important genomic technologies involved in drug discovery, drug development, and genotyping, including DNA sequencing, microarrays, and the quantitative polymerase chain reaction (QPCR). These technologies were discussed in the specific context of drug discovery and development, and in human genotyping of genes involved in drug metabolism and transport. The final 5 weeks were used to review current case studies or examples of pharmacogenetics and drug response. Included were discussions of the pharmacogenetics of drug metabolizing enzymes, drug transporters, cancer therapeutics, organ transplantations, gene therapies, and multiple sclerosis. Guest faculty members were encouraged to use examples of pharmacogenetic principles or methodologies from their research. The final class period was devoted to a discussion of the ethical issues involved in genetic testing, patient stratification, and clinical trials.
One textbook was required, Pharmacogenomics. Applications to Patient Care Modules 1, 2, and 3. 10 A second text, Human Molecular Genetics, Third Edition 11 was strongly recommended. Readings from the current literature were assigned to provide additional background and relevancy to the lecture topics.
Since this was a third-year course for students who would soon begin their advanced pharmacy practice experiences, the course was developed with a format including didactic lectures with active learning in-class activities, a written paper, and examinations composed entirely of written essay questions (Table 2) . A unique feature implemented in the development of this course was the decision to minimize the distribution of prepared class notes by faculty members. As such, students were not provided with notes or note packets prior to each class. The rationale for this decision was that the ability to listen carefully and take accurate notes was an important skill that our students needed to develop. Providing students with the notes prior to each class would not have furthered this goal. 12 Examinations covered approximately one third of the material each and were entirely short answer and essay. Each of the guest faculty members submitted questions for the examinations, which were compiled by the course coordinator. Many of the questions utilized a case-based approach. All examination questions from the previous years were posted online as ''practice examinations.'' Approximately 100 questions for the 3 practice examinations were available to the students. To encourage studentcentered learning, the answers were not provided. The students were encouraged to work out the answers in groups and to meet with faculty members to discuss their answers. Each examination covered material presented since the last examination, though the third examination did include 1 question each from earlier course material. These ''comprehensive'' questions were taken verbatim from the practice examinations.
In-class exercises were given nearly every week and consisted of short-answer problems concerning material covered in the previous lecture or in the assigned readings. The educational goal of the in-class exercises was to keep the students current with the lecture materials and readings and to promote active learning and life-long learning of the topic. An additional benefit was that the in-class work assured nearly 100% attendance. Finally, students were required to write a 2-3 page paper summarizing a current pharmacogenetics paper from the primary literature (Appendix 1). This paper was to be a summary of the recent research, explained at a level such that their fellow students would understand what was In-class activities Short-answer problems based on previous class session done and why it was done. The students had to choose a paper from the current calendar year. This eliminated the possibility of copying the work of students who had taken the course in previous years. Students had no difficulty in finding papers within the current year as the number of publications in the area of pharmacogenomics, pharmacogenetics, and bioinformatics is expanding rapidly. Students had to choose their paper within the first 5 weeks of the course and confirm their choice with the course coordinator in order to avoid multiple students choosing the same paper. Chosen papers were posted weekly so that students could avoid choosing a paper already selected by a classmate. In order to assist students in their writing skills, the instructor provided comments on draft papers. On the due date, students had to submit both a hard copy and an electronic copy of their paper. Students were informed that the electronic copy would be checked for plagiarism using Turnitin (iParadigms, Oakland, Calif, 2006). Feedback from the students was solicited using CourseEval (Academic Management Systems, Buffalo, NY, 2006). Students could evaluate the entire course and each instructor. The evaluation process was done online and all responses were anonymous. Students could submit their evaluations as early as the tenth week of the course, though most did not complete the process until the final weeks. Significance of student responses was evaluated using the Student's t test, corrected for multiple comparisons.
RESULTS
Five hundred twenty-six students have taken the course since spring of 2002. Approximately 95% were in the PharmD program, and the remaining students were bachelor of science, master of science, and doctor of philosophy students in the pharmaceutical sciences.
Students' scores exhibit the typical bell-shaped curve, with approximately 57% scoring 80% or higher. Student course evaluations for the 2002-2005 fall semesters were evaluated and the results are shown in Figure 1 . Between 2003 Between -2005 , approximately 83% (range 77% to 88%) of students completed the course evaluation. In 2002, only 48% of the students completed the required course evaluation. However, this was the first year online course evaluations were utilized in the School and student response rates were low for all courses as students became familiar with the program. Over the 4 years since this course was offered in the fall of the third-professional year, on average, students rated this course a 4 (Likert scale of 1 to 5) with respect to the course outcomes, goals, and objectives being clearly presented in the course syllabus or other provided materials (Q1, Figure 1 ).
Specifically, approximately 76%, 83%, 87%, and 87% of students agreed or strongly agreed that the course outcomes, goals, and objectives were clearly presented in 2002, 2003, 2004 , and 2005, respectively. There was a progressive increase in the student ratings with respect to the course content being consistent with the outcomes, goals, and objectives as shown by the mean values and percentage of students who agreed or strongly agreed (Q2, Figure 1 Based on student written comments, the written paper and essay examination format was one area of controversy as students did not see the relevance of the writing assignment and found the essay examination format challenging based upon their previous educational experiences in the curriculum (multiple-choice examinations). Student evaluations with respect to the availability of course materials by hard copy or an electronic format similarly increased significantly from 3.5 in 2002 to 4.0 in 2005 (Q4, Figure 1 ). Since many of the required courses provided written notes either online or in a packet, students understandably came to expect these and expressed their concern when this material was not provided.
Finally, there was a consistent significant increase in student ratings in the perceived relevancy of this course over the 4 years (Q5, Figure 1 ). Mean student ratings of the relevance of this course material to the future practice of pharmacy and research in the pharmaceutical sciences were 3.4, 4.0, 3.9, and 4. 
DISCUSSION
The principal criticism of the course by students has been the relevancy of the material. Many of the students did not see the importance of genetics as it pertains to the current perceived daily activities of the pharmacist. In some respects this criticism is unavoidable given the newness of this field. Applications of pharmacogenetic data and concepts are just beginning to appear in clinical settings (eg, drug labeling, including statements related to patient specific genetics) and are seldom encountered in community pharmacies. Impressing upon students that their training must anticipate future developments as well as current issues has been challenging. The course has continually been fine tuned to included materials and case studies demonstrating the growing importance of pharmacogenetics in the practice of pharmacy. For example, specific cases from local and national newspapers describing the application of genomics to patient care were highlighted each week. Student evaluations indicated that relevancy was becoming less of an issue, probably due to course improvements and an increasing number of references to this material in other courses, as well as increasing publications in the professional literature and media coverage of pharmacogenetic issues. Similarly, student evaluations concerning course assignments and examinations have also improved. The course has been offered now for more than 5 years and apparently written examinations and course assignments have become more accepted.
CONCLUSIONS
A new required course entitled Principles of the Human Genome, Pharmacogenomics, and Bioinformatics was introduced to the third-year professional PharmD curriculum to strengthen the backgrounds of our students in the latest genomic and bioinformatics technologies and data. Evidence that the objectives of the course are being met are seen in improving students evaluations as well as anecdotal comments from former students who note they are among the few with pharmacogenomic training among their peers.
The course will continue to be offered as a required course in the third-professional year. The relevance of course topics to professional practice will continue to be emphasized, as will ways in which pharmacists can collaborate with other health care professionals both as a resource on pharmacogenetic information and in patient counseling.
